Abstracts Archive - Page 1170 of 2425 - ACR Meeting Abstracts

Abstract Number: 2483 • 2018 ACR/ARHP Annual Meeting
Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Andreas Kerschbaumer¹, Bruno Bierbaumer², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Independent, Munich, Germany, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is among the most intensively studied chronic inflammatory musculoskeletal diseases. Over the past two decades numerous new compounds have been tested…
Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Ayako Kubota¹, Toru Suguro¹, Arata Nakajima², Masato Sonobe³ and Kazuaki Tsuchiya¹, ¹Toho University Omori Medical Center, Tokyo, Japan, ²Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ³Toho University Sakura Medical Center, Chiba, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…
Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting
Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Damemarie Paul¹, Laura McDonald¹, Alexander Marshall², Tammy Curtice³, Melissa Lingohr-Smith⁴, Brandy Menges⁴ and Jay Lin⁴, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Novosys Health, Green Brook, NJ
Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
Abstract Number: 2487 • 2018 ACR/ARHP Annual Meeting
Comparison of QOL Evaluation Using EQ-5D-3L and EQ-5D-5L in Japanese RA Patients: A Study Using the IORRA Cohort
Kumiko Saka¹, Eiichi Tanaka², Eisuke Inoue^1,3, Mai Abe¹, Mika kawano¹, Naohiro Sugitani^1,4, Eri Sugano¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,5, Atsuo Taniguchi¹ and Hisashi Yamanaka⁶, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Toko, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁵Center for Rheumatic Diseases, Mie University Hospital, Tsu, Japan, ⁶Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: EQ-5D-3L is frequently used for evaluation of quality of life (QOL). However, there are several problems when using EQ-5L-3L. Evaluation using EQ-5L-3L might not…
Abstract Number: 2488 • 2018 ACR/ARHP Annual Meeting
Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Marlies C van der Goes¹, Johannes W. G. Jacobs¹, Paco MJ Welsing¹, Désirée van der Heijde², Daniel Aletaha³, Maxime Dougados⁴, Kimme L. Hyrich⁵, Iain B. McInnes⁶, Ulf Müller-Ladner⁷, Ladislav Šenolt⁸, Zoltan Szekanecz⁹, Jacob van Laar¹ and Gyorgy Nagy¹⁰, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK, Glasgow, United Kingdom, ⁷Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ⁸First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁹Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary, ¹⁰Department of Genetics, Cell- and Immunobiology & Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, Budapest, Hungary
Background/Purpose: EULAR and ACR recommendations on the management of rheumatoid arthritis (RA) mainly focus on early RA and medication.1,2 Following these recommendations, several patients nevertheless…
Abstract Number: 2489 • 2018 ACR/ARHP Annual Meeting
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Irini Genitsaridi^1,2, Irini Flouri³, Argyro Repa², Nestor Avgoustidis², Nikolaos Kougkas², Ioannis Papalopoulos², Styliani Polia², Konstantinos Marias¹, Dimitris Plexousakis⁴, George Bertsias² and Prodromos Sidiropoulos², ¹Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece, ²Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ³Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklio, Greece, ⁴Information Systems Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece
Background/Purpose: Registry data have shown that treatment with bDMARDs induces remission or LDA (RLDA) in up-to 50% of RA patients. Approximately 30-50% of patients have…
Abstract Number: 2490 • 2018 ACR/ARHP Annual Meeting
Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?
Sergio Schwartzman¹, Dennis Parenti², Shawn Black², Stephen Xu³, Wayne Langholff³ and Shelly Kafka², ¹Weill Cornell Medical College, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing prospective Phase 4 comparator study designed to provide…
Abstract Number: 2491 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Jing Yang¹, Hua Wei², Jianlin Huang³, Wenqiang Fan⁴, Hongzhi Wang⁵, Yongfu Wang⁶, Rong Mu⁷, Chun Li⁸, Jinmei Zou¹, Yu Zhang¹, Bin Wu⁹, Jianling Dong¹, Xiaofei Shi¹⁰, Xinwang Duan¹¹, Jianhong Wu¹², Fang He¹³, Hong Liu¹, Zhijun Li¹⁴, Guosheng Wang¹⁵, Shengguang Li¹⁶, Bei Wang¹⁷, Yanjie Hao¹⁸, Huiqiong Zhou¹⁹, Haili shen²⁰, Yang Cui²¹, Wenhui Huang²², Qing-chun Huang²³, Hui Xiao²⁴, Yuhua Jia²⁴, Fei Xiao²⁴ and Feng-Chun Zhang²⁵, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵The First Hospital of Jiaxing, Jiaxing, China, ⁶The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁷Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁸Peking University People's Hospital, Beijing, China, ⁹Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹¹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹²Dazhou Central Hospital, Dazhou, China, ¹³Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁵Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹⁶Peking University International Hospital, Beijing, China, ¹⁷Beijing Hospital of Traditional Chinese Medicine (TCM), Beijing, China, ¹⁸The First Affiliated Hospital of Beijing University, Beijing, China, ¹⁹The First Affiliated Hospital of PLA General Hospital, Beijing, China, ²⁰Department of Rheumatology and Immunology, Second Hospital of Lanzhou University, lanzhou, China, ²¹Guangdong General Hospital, Guangzhou, China, ²²The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ²³Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: T2T, achieving a DAS28 score lower than 3.2 is the main management strategy recommended by ACR and EULAR. HAQ is the most widely used…
Abstract Number: 2492 • 2018 ACR/ARHP Annual Meeting
Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Chun Li², Jing Yang³, Hua Wei⁴, Jianlin Huang⁵, Wenqiang Fan⁶, Yongfu Wang⁷, Hongzhi Wang⁸, Jinmei Zou³, Xiaofei Shi⁹, Xiafei Xin¹⁰, Jianhong Wu¹¹, Fen Li¹², Shouxin Li¹³, Huiqin Yang¹⁴, Anbing Zhang¹⁵, Dongbao Zhao¹⁶, Jinchang He¹⁷, Junli Zhang¹⁸, Luo Li¹⁹, Peng Ji²⁰, Xiaofeng Rong²¹, Feng Jiang²², Ling Wang²³, Yuhua Jia²⁴, Fei Xiao²⁴ and Zhan-Guo Li²⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Northern Jiangsu People's Hospital, Yangzhou, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁷The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁸The First Hospital of Jiaxing, Jiaxing, China, ⁹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁰Ningbo First Hospital, Zhejiang, Ningbo, China, ¹¹Dazhou Central Hospital, Dazhou, China, ¹²The Second Xiangya Hospital of Central South University, Changsha, China, ¹³Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ¹⁴Wuhan No 1 Hospital, wuhan, China, ¹⁵Xiangyang Central Hospital, Xiangyang, China, ¹⁶Changhai Hospital of Shanghai, Shanghai, China, ¹⁷PanZhiHua Central Hospital, Panzhihua, China, ¹⁸Xi 'an no.5 hospital, Xian, China, ¹⁹The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ²⁰[email protected], Wulumuqi, China, ²¹Affiliated hospital of Chongqing medical University, Chongqing, China, ²²Huzhou Third People's Hospital, Huzhou, China, ²³Zao Zhuang Municipal Hospital, zaozhuang, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 score lower than 2.6 (remission, Rem) or below 3.2 (low disease activity, LDA), is the main management strategy recommended…
Abstract Number: 2493 • 2018 ACR/ARHP Annual Meeting
Features of Disease Severity Associated with Patient Satisfaction with Biologic Treatment: Results from the Abatacept Best Care Real-World Study
Boulos Haraoui¹, Janet E. Pope², Emmanouil Rampakakis³, Julie Vaillancourt³, Meryem Maoui⁴ and Louis Bessette⁵, ¹Université de Montréal, Montreal, QC, Canada, ²St. Joseph’s Health Care, London, ON, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Bristol-Myers Squibb, Montreal, QC, Canada, ⁵Laval University, Québec, QC, Canada
Background/Purpose: Patients satisfaction with their treatment is important for adherence to medications, particularly for chronic conditions such as rheumatoid arthritis (RA). The aim of this…
Abstract Number: 2494 • 2018 ACR/ARHP Annual Meeting
Relationship between Specific Joint Involvement and Work/Activity Impairment in Rheumatoid Arthritis Patients: Implications for Clinical Practice
Boulos Haraoui¹, Janet E. Pope², Emmanouil Rampakakis³, Julie Vaillancourt³, Meryem Maoui⁴ and Louis Bessette⁵, ¹Université de Montréal, Montreal, QC, Canada, ²St. Joseph’s Health Care, London, ON, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Bristol-Myers Squibb, Montreal, QC, Canada, ⁵Laval University, Québec, QC, Canada
Background/Purpose: Swelling or tenderness of specific joints may differentially impact the ability of rheumatoid arthritis (RA) patients to perform daily activities and work. The aim…
Abstract Number: 2495 • 2018 ACR/ARHP Annual Meeting
Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters
Carson Maynard¹, Ted R. Mikuls², Grant W. Cannon³, Bryant R. England⁴, Gail S. Kerr⁵, Jennifer Barton⁶ and Joshua Baker⁷, ¹Division of Rheumatology, Philadelphia VA Medical Center and University of Pennsylvania, PHILADELPHIA, PA, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁶VA Portland Health Care System and Oregon Health and Science, Portland, OR, ⁷Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA
Background/Purpose: In rheumatoid arthritis (RA), women may be less likely to achieve clinical remission. These sex differences remain incompletely understood and might relate to differences…
Abstract Number: 2496 • 2018 ACR/ARHP Annual Meeting
Determination of the Minimally Important Difference for Interpreting the RA Multi-Biomarker Disease Activity Test Score: Impact of Diurnal and Daily Biomarker Variation on Scores Adjusted for Age, Sex and Adiposity
David Chernoff¹, P. Scott Eastman², Darl D. Flake II³, Alan J. Kivitz⁴ and Jeffrey R. Curtis⁵, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Senior Director, New Product Development, Crescendo Bioscience Inc., South San Francisco, CA, ³Myriad Genetics Inc., Salt Lake City, UT, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Previous studies have demonstrated the efficacy of a treat-to-target approach to optimize therapeutic outcomes for patients with RA using measures of clinical disease activity…
Abstract Number: 2497 • 2018 ACR/ARHP Annual Meeting
The Relationship between Difficulty Affording Arthritis Medications and Illness Intrusiveness in Rheumatoid Arthritis Patients: A Longitudinal Study
Genevieve Hickey¹, Caprice Hunt¹, Delesha M. Carpenter², Elizabeth (Blair) Solow³, Valerie Reyna⁴, Cynthia Edmonds¹, Gail Tudor⁵, Kimberlee O'Neill¹, Lisa Schwartz⁶, Molly Keebler⁷, Steven Woloshin⁶ and Susan J. Blalock¹, ¹Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Asheville, NC, ³UT Southwestern Rheumatology, Dallas, TX, ⁴Cornell University, Ithica, NY, ⁵Institutional Research, Husson University, Bangor, ME, ⁶Geisel School of Medicine, Dartmouth, Hanover, NH, ⁷Center for BrainHealth, University of Texas Dallas, Dallas, TX
Background/Purpose: We examined the relationship between the difficulty rheumatoid arthritis (RA) patients have being able to afford their arthritis medications and illness intrusiveness. Illness intrusiveness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].